Patent ID: 6270797
Filing Date: 2001-08-07
Classification: A61K

Abstract:
A sustained release glipizide composition that releases glipizide in conformity to a zero-order kinetics and results in a serum plasma glipizide concentration of at least 50 ng/ml twenty-four hours after administration of a single dose of said composition, comprising:a. glipizide in an amount from 2-5 percent by weight;b. at least one hydrophilic polymer selected from a group consisting of hydroxypropylmethylcellulose having a molecular weight of 26,000-86,000, a methoxy degree of substitution of 1.36-1.90, and a hydroxypropyl molar substitution of 0.18-0.25, and hydroxypropylcellulose having a molecular weight of 80,000-115,000, in an amount from 65-75 percent by weight;c. a diluent selected from a group consisting of polyvinylpyrrolidone, microcrystalline cellulose and gum arabic, in an amount from 1.5-4.0 percent by weight;d. at least one flow regulating agent selected from a group consisting of colloidal silicon dioxide, talc and starch, in an amount from 1-2 percent by weight;e. a lubricant selected from a group consisting of magnesium stearate and zinc stearate, in an amount from 0.5-1.5 percent by weight; andf. at least one other excipient, in a percentage amount by weight such that a total weight of said composition is 100 percent;said composition further comprising an oral dosage form having from 2.5-20 mg glipizide.